Targeting hexokinase 2 for oral cancer therapy: structure-based design and validation of lead compounds
Open Access
- 11 March 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1346270
Abstract
The pursuit of small molecule inhibitors targeting hexokinase 2 (HK2) has significantly captivated the field of cancer drug discovery. Nevertheless, the creation of selective inhibitors aimed at specific isoforms of hexokinase (HK) remains a formidable challenge. Here, we present a multiple-pharmacophore modeling approach for designing ligands against HK2 with a marked anti-proliferative effect on FaDu and Cal27 oral cancer cell lines. Molecular dynamics (MD) simulations showed that the prototype ligand exhibited a higher affinity towards HK2. Complementing this, we put forth a sustainable synthetic pathway: an environmentally conscious, single-step process facilitated through a direct amidation of the ester with an amine under transition-metal-free conditions with an excellent yield in ambient temperature, followed by a column chromatography avoided separation technique of the identified lead bioactive compound (H2) that exhibited cell cycle arrest and apoptosis. We observed that the inhibition of HK2 led to the loss of mitochondrial membrane potential and increased mitophagy as a potential mechanism of anticancer action. The lead H2 also reduced the growth of spheroids. Collectively, these results indicated the proof-of-concept for the prototypical lead towards HK2 inhibition with anti-cancer potential.Keywords
This publication has 54 references indexed in Scilit:
- The development of small-molecule inhibitors targeting hexokinase 2Drug Discovery Today, 2022
- Methylglyoxal induces ambience for cancer promotion in HepG2 cells via Warburg effect and promotes glycationJournal of Cellular Biochemistry, 2022
- Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of ActionJAMA Network Open, 2021
- Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategyBioorganic & Medicinal Chemistry Letters, 2021
- Structure based discovery of novel hexokinase 2 inhibitorsBioorganic Chemistry, 2020
- Hexokinase 2 dimerization and interaction with voltage‐dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancerCancer Medicine, 2019
- Mitophagy and Quality Control Mechanisms in Mitochondrial MaintenanceCurrent Biology, 2018
- VDAC in cancerBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2017
- Emodin targets mitochondrial cyclophilin D to induce apoptosis in HepG2 cellsBiomedicine & Pharmacotherapy, 2017
- Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of CancerCancer Cell, 2013